Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploratory study for implementing a Global Burden of Animal Diseases case study in Senegal.

Revue scientifique et technique (International Office of Epizootics)·2024

Same author

Study of the Phytochemical Composition, the Antioxidant and the Anti-Inflammatory Effects of Two Sub-Saharan Plants: <i>Piliostigma reticulatum</i> and <i>Piliostigma thonningii</i>.

Advances in pharmacological and pharmaceutical sciences·2021

Same author

Comment on: Guidelines for treatment of umbilical and epigastric hernias from the European Hernia Society and Americas Hernia Society.

The British journal of surgery·2020

Same author

Unusual extra-podal fungal mycetoma with black grains in a Senegalese child.

Journal de mycologie medicale·2019

Same author

Correlation between olfactory function, trigeminal sensitivity, and nasal anatomy in healthy subjects.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2019

Same author

[Assistance and Support Units for the elderly: A tool for promoting health in seniors: Example of the CAAPA unit of "Sicap Rue 10", in Dakar].

Le Mali medical·2018

Search research articles

Related Experiment Videos

[Leg ulcer due to hydroxyurea. A case report].

S B Gning¹, J M Debonne, N M Diagne-Guèye

¹Services médicaux. Hôpital Principal de Dakar, BP 3006, Dakar, Sénégal. saragning@yahoo.fr

Dakar Medical

|July 18, 2007

Summary

Hydroxyurea, used for myeloproliferative syndromes, can cause leg ulcers. Stopping this antineoplastic agent led to the healing of a patient's leg ulcer, highlighting a rare side effect.

Related Experiment Videos

Area of Science:

Dermatology
Hematology
Oncology

Background:

Hydroxyurea is an antineoplastic agent used for myeloproliferative syndromes and other conditions.
Dermatological side effects, including leg ulcers, are recognized complications of prolonged hydroxyurea therapy.

Observation:

A 47-year-old female patient with chronic myelogenous leukemia developed a painful left ankle ulcer with purulent discharge.
The patient was receiving hydroxyurea 1500 mg daily, with documented hyperleukocytosis and Pseudomonas aeruginosa infection in the ulcer.
No signs of vascular compromise were noted, and blood cultures were negative.

Findings:

Discontinuation of hydroxyurea treatment resulted in the complete healing of the leg ulcer within two months.
The patient's leg ulcer was attributed to hydroxyurea therapy, a rarely reported adverse event.

Implications:

The occurrence of leg ulcers necessitates the cessation of hydroxyurea treatment.
This case underscores the importance of recognizing uncommon dermatological manifestations of hydroxyurea therapy.